Clopidogrel
Product Images NDC 52605-083

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 52605-083). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Polygen Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clopidogrel-300mg-30s (Clopidogrel 300mg 30s)

Clopidogrel Tablets USP 300 mg film-coated tablet label showing active ingredient strength, dispensing instructions, storage conditions, child-resistant packaging warning, manufacturer Polygen Pharmaceuticals Inc., package size of 30 tablets, and barcode with NDC 52605-083-13. Label includes instructions for pharmacists to dispense Medication Guide.*

FDA Label Image

Clopidogrel-300mg-500s (Clopidogrel 300mg 500s)

Clopidogrel Tablets, USP 300 mg film-coated tablets label from Polygene Pharmaceuticals Inc. The label shows dosage information, storage instructions, and packaging details for a container of 500 tablets. Includes NDC 52605-083-05, barcode, and a section for lot and expiration dates.*

FDA Label Image

Clopidogrel-75mg-1000s (Clopidogrel 75mg 1000s)

Label for Clopidogrel Tablets, USP 75 mg by Polygen Pharmaceuticals Inc. The label states each film-coated tablet contains 97.875 mg clopidogrel bisulphate, USP equivalent to 75 mg clopidogrel. The package contains 1000 tablets, is Rx only, and includes storage instructions and pharmacist dispensing guidance.*

FDA Label Image

Clopidogrel-75mg-30s (Clopidogrel 75mg 30s)

Clopidogrel Tablets, USP 75 mg package label by Polygen Pharmaceuticals Inc. The label states each film-coated tablet contains 97.875 mg of clopidogrel bisulphate, equivalent to 75 mg of clopidogrel. It includes storage instructions and advises dispensing with medication guide. The package contains 30 tablets and is marked Rx Only.*

FDA Label Image

Fig1 (Clopidogrel Figure1)

A chart illustrating the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite AUC with mean and 90% confidence intervals. Four PPIs are listed: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, each shown with a horizontal confidence interval bar relative to a reference value centered at 1.0 on the x-axis.*

FDA Label Image

Fig2 (Clopidogrel Figure2)

A cumulative event rate line graph showing cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. It compares clopidogrel tablets plus aspirin to placebo plus aspirin, with the clopidogrel group showing a lower event rate throughout the timeline. The graph includes a statistical significance value (P = 0.00009) and notes that other standard therapies were used as appropriate.*

FDA Label Image

Fig3-ctd (Clopidogrel Figure3 Ctd)

A forest plot chart depicting hazard ratios with 95% confidence intervals for Clopidogrel versus placebo across various subgroups including Heparin/LMWH use, Aspirin dosage, GPIIb/IIIa antagonist use, Beta-Blocker use, and ACE inhibitor use. The plot visually compares the incidence of events favoring Clopidogrel or placebo in each subgroup and overall.*

FDA Label Image

Fig3 (Clopidogrel Figure3)

A forest plot chart showing hazard ratios with 95% confidence intervals comparing Clopidogrel and placebo across various subgroups including age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke. The chart visually represents favorability between Clopidogrel and placebo in these subgroups.*

FDA Label Image

Fig4 (Clopidogrel Figure4)

This is a Kaplan-Meier survival curve chart depicting the percentage of patients dead before first discharge over time (days since randomization, up to 28 days) comparing Clopidogrel to placebo. The chart shows mortality rates and a calculated proportional risk reduction favoring Clopidogrel.*

FDA Label Image

Fig5 (Clopidogrel Figure5)

A Kaplan-Meier curve chart depicting the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days comparing Clopidogrel versus placebo, showing events for 2121 and 2310 patients respectively and a 9% proportional risk reduction for Clopidogrel. All treated patients received aspirin.*

FDA Label Image

Fig6 (Clopidogrel Figure6)

A forest plot depicting odds ratios with 99% confidence intervals for Clopidogrel tablets versus placebo across various subgroups including gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The plot includes sample sizes and percentage event rates for each subgroup, with an overall summary estimate at the bottom.*

FDA Label Image

Fig7 (Clopidogrel Figure7)

A line graph titled 'Fatal or Non-Fatal Vascular Events' showing cumulative event rate (%) on the y-axis over months of follow-up (0 to 36) on the x-axis. Two lines compare the cumulative event rates for aspirin and clopidogrel tablets, with aspirin generally showing a higher event rate. The graph includes a p-value of 0.045, indicating statistical comparison between the treatments.*

FDA Label Image

Fig8 (Clopidogrel Figure8)

A hazard ratio forest plot comparing Clopidogrel tablets to Aspirin for qualifying conditions including Stroke, MI, and PAD. The plot shows number of events and percentages for each group, with a summary overall hazard ratio and 95% confidence intervals displayed on the horizontal axis.*

FDA Label Image

Clopidogrel-structure (Clopidogrel Structure)

Chemical structure diagram of Clopidogrel with a sulfate (H2SO4) component shown. The structure includes a bicyclic thienopyridine ring, a methyl ester group, and a chlorophenyl moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.